|
Osteopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Heamatococcus pluvialis ameliorates bone loss in experimentally-induced osteoporosis in rats via the regulation of OPG/RANKL pathway.
|
31158803 |
2019 |
|
Osteopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Within the limitations of the study, certain genes involved in bone remodeling (runt-related transcription factor-2 [Runx-2], bone morphogenetic protein-2 [BMP-2], and peroxisome proliferator-activated receptor gamma-2 [PPARγ-2]) and RANKL/OPG are correlated with early periimplant bone loss, with the type of suprastructure and the involved jaw being significant clinical factors.
|
31306296 |
2019 |
|
Osteopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared with the OVX group, ZGW groups showed significantly reduced levels of serum tartrate-resistant acid phosphatase 5b (TRACP-5b) and β-cross-linked c-telopeptide of type I collagen (β-CTX) (P ＜ 0.01), increased levels of serum bone-specific alkaline phosphatase (BALP) (P ＜ 0.01) and OPG (P ＜ 0.05), prevention of OVX-induced bone loss, and improved microarchitecture of the trabecular bone of distal femur.
|
29710663 |
2018 |
|
Osteopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These features have been associated with bone loss and OPG production.
|
29383454 |
2018 |
|
Osteopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hydrogen sulfide epigenetically mitigates bone loss through OPG/RANKL regulation during hyperhomocysteinemia in mice.
|
29908298 |
2018 |
|
Osteopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is demonstrated that HYA not only promoted bone formation in normal zebrafish (compared to <i>Control</i> group), but also reversed glucocorticoid induced bone loss (compared to <i>Prednisolone</i> group) according to the intervention of HYA in upregulating the area of mineralized bones (<i>p</i> < 0.01), increasing cumulative optical density (<i>p</i> < 0.01), promoting bone formation related gene expression (AKP, Type I, Runx2, OPG, and OCN, <i>p</i> < 0.01), inhibiting bone resorption related gene expression (TRACP, <i>p</i> < 0.01), and elevating whole-body trace mineral elements (Ca, P, K, Mg, Zn, and Fe) levels (<i>p</i> < 0.01).
|
30069475 |
2018 |
|
Osteopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
|
28580511 |
2017 |
|
Osteopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Regression analysis showed that the presence of OPG-Ab was independently associated with total hip osteopenia (OR<sub>adj</sub> 24.2; 95% CI 2.57, 228) and history of fractures (OR<sub>adj</sub> 10.5; 95% CI 2.07, 53.3).
|
28534161 |
2017 |
|
Osteopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hyperparathyroidism in humans and continuous parathyroid hormone (cPTH) treatment in mice cause bone loss by regulating the production of RANKL and OPG by stromal cells (SCs) and osteoblasts (OBs).
|
20808842 |
2010 |
|
Osteopenia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
All this could suggest that the greater bone loss that characterizes OP patients can be mediated due to differences in the secretion and expression of the RANKL/OPG system in response to different stimuli.
|
19073256 |
2009 |
|
Osteopenia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Systemic administration of OPG expressing MSC reduced osteoclast activation (P<0.01) and trabecular bone loss in the vertebrae (P<0.05) and tibiae of diseased animals, to levels comparable to non-diseased controls.
|
17657224 |
2007 |
|
Osteopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, it is not known which factors regulate RANKL and OPG in human inflammation-induced bone loss.
|
11281165 |
2001 |